SCHEMBL396153

SCHEMBL396153

Cc1ccc(NC(=O)c2ccccc2)cc1Nc1cccc2c1NC(=O)C2=Cc1[nH]c(C)c(C(=O)NCCN2CCCC2)c1C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 7/20 0.55
PDGFRB P09619 5/20 0.55
FLT3 P36888 4/20 0.55
AURKB Q96GD4 3/20 0.55
MET P08581 1/20 0.55
FGFR1 P11362 4/20 0.55
TLK2 Q86UE8 2/20 0.55
KIT P10721 3/20 0.51
AURKA O14965 1/20 0.51
LCK P06239 1/20 0.51
KCNH2 Q12809 1/20 0.51
NTRK2 Q16620 1/20 0.46
PRKAA2 P54646 3/20 0.44
PRKAA1 Q13131 3/20 0.44
PIM1 P11309 2/20 0.44
PIM2 Q9P1W9 1/20 0.44
NTRK1 P04629 1/20 0.43
PDPK1 O15530 2/20 0.42
AKT2 P31751 2/20 0.42
FLT4 P35916 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10091913 1.00 KDR (0.55) KDRPDGFRBFLT3AURKBMET
SCHEMBL394470 0.92 KDR (0.57) KDRPDGFRBFLT3AURKBMET
SCHEMBL10091907 0.92 KDR (0.57) KDRPDGFRBFLT3AURKBMET
SCHEMBL10091917 0.89 KDR (0.65) KDRPDGFRBFLT3AURKBMET
SCHEMBL396419 0.89 KDR (0.66) KDRPDGFRBFLT3AURKBMET
SCHEMBL10091904 0.89 KDR (0.66) KDRPDGFRBFLT3AURKBMET
SCHEMBL396165 0.89 KDR (0.65) KDRPDGFRBFLT3AURKBMET
SCHEMBL10091912 0.88 KDR (0.54) KDRPDGFRBFLT3AURKBMET
SCHEMBL395037 0.88 KDR (0.54) KDRPDGFRBFLT3AURKBMET
SCHEMBL4138549 0.87 FLT3 (0.55) KDRPDGFRBFLT3AURKBMET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101608-B2 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems IRM LLC, a Delware Limited Corporation (BM) 2012-01-24 US claimed
US-8101608-B2 3-(4-Methyl-imidazol-1-yl)-N-{3-[2-oxo-3-(1H-pyrrol-2-ylmethylene)-2,3-dihydro-1H-indol-6-ylamino]-phenyl}-5-trifluoromethyl-benzamide; including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune and nervous systems IRM LLC, a Delware Limited Corporation (BM) 2012-01-24 US disclosed